Tokyo Tape
Sign in
← Soiken Holdings

Quarterly report · Q2

2385.TEDINET S100Q4ZE
Period2022-07-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥4.2bn2022-07-01 → 2022-12-31Cons.Net sales
Revenue¥9.3bn2021-07-01 → 2022-06-30Cons.Net sales (5-year summary)
Revenue¥5.2bn2021-07-01 → 2021-12-31Cons.Net sales
Operating income¥345m2022-07-01 → 2022-12-31Cons.Operating income
Operating income¥584m2021-07-01 → 2021-12-31Cons.Operating income
Ordinary income¥345m2022-07-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.3bn2021-07-01 → 2022-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥629m2021-07-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥345m2022-07-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥628m2021-07-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥209m2022-07-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥810m2021-07-01 → 2022-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥415m2021-07-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥213m2022-07-01 → 2022-12-31Cons.Profit loss
Net income¥421m2021-07-01 → 2021-12-31Cons.Profit loss
Total assets¥8.0bnat 2022-12-31Cons.Assets
Total assets¥8.5bnat 2022-06-30Cons.Assets
Total assets¥8.1bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥1.0bnat 2022-12-31Cons.Liabilities
Total liabilities¥1.6bnat 2022-06-30Cons.Liabilities
Net assets / equity¥6.9bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.8bnat 2022-06-30Cons.Net assets
Net assets / equity¥6.5bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥5.5bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥6.0bnat 2022-06-30Cons.Cash and deposits
Cash & equivalents¥5.5bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥6.0bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.3bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.3bnat 2021-06-30dCons.Cash and cash equivalents
Operating cash flow−¥328m2022-07-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.1bn2021-07-01 → 2022-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.2bn2021-07-01 → 2021-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥27m2022-07-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥245m2021-07-01 → 2022-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥23m2021-07-01 → 2021-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥130m2022-07-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥130m2021-07-01 → 2022-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥129m2021-07-01 → 2021-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥82022-07-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥7.472022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥30.952021-07-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.862021-07-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥12.712021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio84.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio78.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio77.4%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 48
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-12-31−¥2m
Reconciling Itemsreconcilingrevenue external2022-07-01 → 2022-12-31¥900,000
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-12-31−¥3m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-12-31−¥155m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentrevenue2022-07-01 → 2022-12-31¥258m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentrevenue external2022-07-01 → 2022-12-31¥258m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentsegment profit2022-07-01 → 2022-12-31¥32m
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentrevenue2022-07-01 → 2022-12-31¥2.0bn
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentrevenue external2022-07-01 → 2022-12-31¥2.0bn
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentsegment profit2022-07-01 → 2022-12-31¥398m
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue external2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentsegment profit2022-07-01 → 2022-12-31−¥18m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue2022-07-01 → 2022-12-31¥279m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue external2022-07-01 → 2022-12-31¥277m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue intersegment2022-07-01 → 2022-12-31¥3m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentsegment profit2022-07-01 → 2022-12-31¥43m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentrevenue2022-07-01 → 2022-12-31¥314m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentrevenue external2022-07-01 → 2022-12-31¥314m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentsegment profit2022-07-01 → 2022-12-31¥45m
—segment totalrevenue2022-07-01 → 2022-12-31¥4.2bn
—segment totalrevenue external2022-07-01 → 2022-12-31¥4.2bn
—segment totalrevenue intersegment2022-07-01 → 2022-12-31¥3m
—segment totalsegment profit2022-07-01 → 2022-12-31¥500m
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-12-31−¥2m
Reconciling Itemsreconcilingrevenue external2021-07-01 → 2021-12-31¥900,000
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-12-31−¥3m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-12-31−¥162m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentrevenue2021-07-01 → 2021-12-31¥231m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentrevenue external2021-07-01 → 2021-12-31¥231m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentsegment profit2021-07-01 → 2021-12-31−¥6m
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentrevenue2021-07-01 → 2021-12-31¥2.7bn
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentrevenue external2021-07-01 → 2021-12-31¥2.7bn
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentsegment profit2021-07-01 → 2021-12-31¥659m
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue2021-07-01 → 2021-12-31¥1.6bn
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue external2021-07-01 → 2021-12-31¥1.6bn
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentsegment profit2021-07-01 → 2021-12-31−¥22m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue2021-07-01 → 2021-12-31¥360m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue external2021-07-01 → 2021-12-31¥358m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue intersegment2021-07-01 → 2021-12-31¥3m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentsegment profit2021-07-01 → 2021-12-31¥63m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentrevenue2021-07-01 → 2021-12-31¥315m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentrevenue external2021-07-01 → 2021-12-31¥315m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentsegment profit2021-07-01 → 2021-12-31¥52m
—segment totalrevenue2021-07-01 → 2021-12-31¥5.2bn
—segment totalrevenue external2021-07-01 → 2021-12-31¥5.1bn
—segment totalrevenue intersegment2021-07-01 → 2021-12-31¥3m
—segment totalsegment profit2021-07-01 → 2021-12-31¥746m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 442
ItemContextValueUnit
Payments for guarantee deposits inv cfPrior1YTDDuration－JPY
Payments for guarantee deposits inv cfCurrentYTDDuration-102000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-23352000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-27023000JPY
Cash dividends paid fin cfPrior1YTDDuration-129469000JPY
Cash dividends paid fin cfCurrentYTDDuration-129936000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-129469000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-129936000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration1079378000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration-484857000JPY
Cash and cash equivalentsPrior2YearInstant4255805000JPY
Cash and cash equivalentsPrior1YearInstant6017253000JPY
Cash and cash equivalentsPrior1QuarterInstant5335183000JPY
Cash and cash equivalentsCurrentQuarterInstant5532396000JPY
Advertising expenses sgaPrior1YTDDuration544957000JPY
Advertising expenses sgaCurrentYTDDuration478715000JPY
Research and development expenses sgaPrior1YTDDuration14689000JPY
Research and development expenses sgaCurrentYTDDuration20122000JPY
Depreciation sgaPrior1YTDDuration8153000JPY
Depreciation sgaCurrentYTDDuration7942000JPY
Provision of allowance for doubtful accounts sgaPrior1YTDDuration3884000JPY
Provision of allowance for doubtful accounts sgaCurrentYTDDuration-4180000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember231132000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember314923000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember2677275000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember1568557000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember357720000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember5149609000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember900000JPY
Revenues from external customersPrior1YTDDuration5150509000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember2638000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember2638000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-2638000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember231132000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember314923000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember2677275000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember1568557000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember360359000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember5152248000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-1738000JPY
Net salesPrior1YTDDuration5150509000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember-6034000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember51785000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember659140000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember-22135000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-06-30pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-07-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-07-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-07-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass